Article | March 22, 2021

Elevating Effective Outcomes With Companion Diagnostics

Source: Q2 Solutions

By Alan Wookey

Medical professional with globe

The successful development and commercialization of personalized medicines often necessitate use of companion diagnostics (CDx).

Now more than ever, drug developers need an experienced global partner to advance CDxdevelopment, who understands how to navigate the technical, regulatory and commercialization nuances to enhance the chances of program success.

Additionally, there is a sharpening focus toward smaller populations treated with drugs for orphan indications and rare diseases, umbrella clinical trials where targeted drugs are used for multiple tumor mutations, and basket clinical trials where targeted drugs focus on multiple tumor indications.

The improvements that precision medicine brings to patient outcomes are increasingly being implemented in clinical practices worldwide. Companion diagnostics are assays that are required to be used before a specific therapy can be initiated. They are often co-developed alongside a therapeutic during its clinical development journey. Extensive testing in clinical trials is required, often in multiple sites across the globe.

Companion diagnostics (CDx) is a keystone for pharma to create more precise drug therapies as personalized medicine accelerates. Here’s why a CDxcentral laboratory partner is necessary.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader